The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).